Purchase Order 75N91024P00070
Award Date
11/15/23
Potential Completion Date
12/7/24
Potential Value
$20K
Federal Agency
National Cancer Institute
Awardee
Illumina, Inc.
Ultimate Awardee
Not listed
NAICS Category
811310 - Commercial and Industrial Machinery and Equipment (except Automotive and Electronic) Repair and Maintenance
PSC Category
6640 - Laboratory Equipment And Supplies
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92122, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This firm fixed-price delivery order was awarded by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to Illumina, Inc., a for-profit manufacturer of sequencing and array-based genomics analysis products. The $28,701.70 contract is for the provision of various Illumina sequencing instruments, reagents, and related services. This award does not have a set-aside designation. Through prior prime and subcontract awards, Illumina has supported...
This is a firm fixed-price delivery order awarded by the National Cancer Institute, a civilian agency under the Department of Health and Human Services, to Illumina, Inc., a for-profit manufacturer of genomic sequencing and analysis products. The $24,230.96 contract provides Illumina sequencing systems, reagents, and services to support genomic research and diagnostics. The award is not associated with a set-aside program. Through past prime contract and subcontract awards, Illumina has...
This contract was awarded by the National Cancer Institute (NCI), a civilian agency under the National Institutes of Health (NIH), to Illumina, Inc., a for-profit manufacturer of genetic analysis instruments and reagents. The $24,797.20 firm-fixed-price delivery order is for Illumina's sequencing systems, reagents, and consumables to support genomic sequencing and analysis research and diagnostics. No set-aside was used. Illumina has a history of providing these types of products and services to...
This is a $28,749.60 firm-fixed-price delivery order contract awarded by the National Cancer Institute (NCI) to Illumina, Inc., a manufacturer of sequencing and array-based genomic analysis solutions. The contract is for the provision of laboratory equipment and supplies, with no set-aside designation. Through this award, Illumina will provide the NCI with a range of its NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems, as well as accompanying reagents, consumables, sample prep kits,...
This is a $142,990 firm fixed price purchase order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Illumina, Inc., a manufacturer of genomic sequencing systems and analytical instruments. The contract has no set-aside designation. Illumina has previously received prime federal contract awards from other agencies like the CDC, USDA, and VA to provide sequencing systems, reagents, and related services in support of genomics...
This is a $17,508.94 firm fixed price delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency of the U.S. government, to Illumina, Inc., a for-profit manufacturer of sequencing and genomic analysis instruments and reagents. The contract is not set aside for any special designation. Illumina has previously been awarded prime federal contracts and subcontracts by agencies like the NIH, CDC, USDA, and VA to provide a range of sequencing systems, consumables, and...
This is a firm fixed price delivery order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and reagents. The $13,438.88 contract is for the provision of Illumina's NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems, along with related consumables, support services, and bioinformatics products to support genomic research and diagnostics projects at the...
This contract was awarded by the National Cancer Institute (NCI), a civilian agency under the Department of Health and Human Services, to Illumina, Inc., a for-profit manufacturer of genomic sequencing and analysis solutions. The contract, valued at $35,959.68, is for the delivery of biological kits and has a completion date of April 30, 2025. It is a firm fixed-price delivery order contract with no set-aside designation. Illumina, a leading provider of genomic sequencing technologies, has...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $228,009.60 firm fixed price delivery order to Illumina, Inc., a for-profit manufacturer of genomic sequencing instruments and reagents. The contract is for the provision of reagents and consumables, with a completion date of April 21, 2023. This award is not associated with a set-aside program. Illumina has a history of providing sequencing systems, reagents, and services to support...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute awarded a $228,009.60 firm fixed-price delivery order contract to Illumina, Inc., a for-profit manufacturer of genomic sequencing instruments and reagents. The contract has a completion date of March 19, 2024 and is for the provision of biological kits. Illumina has a history of providing sequencing systems, consumables, and bioinformatics products to federal agencies like the NIH,...